Shire buys ViroPharma in $4.2 billion deal (Update)

The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.

The Dublin-based drugmaker said Monday it will pay $50 for each share of ViroPharma, which is based in Exton, Pa. That represents a 27 percent premium on the U.S. company's closing price Friday, the last trading day before the deal was announced.

Shares of ViroPharma soared before markets opened and after the deal was announced, while Shire's U.S.-traded stock also climbed.

ViroPharma focuses on serious diseases with few, if any, available therapies. Its products include Cinryze, which is used to prevent and treat attacks of hereditary angioedema, a rare genetic disorder that can cause dangerous swelling of the throat or larynx.

It also makes the seizure drug Buccolam and antibiotic Vancocin.

The company generated $428 million in worldwide revenue last year.

ViroPharma said last month that U.S. sales of Cinryze, which accounts for most of its revenue, climbed 22 percent in the third quarter to $102.2 million. It expects North American sales for the treatment to total $405 million this year.

Shire said Cinryze will act as a complement to one if its drugs, Firazyr, which treats acute hereditary angioedema attacks.

ViroPharma also is developing maribavir, a potential treatment for a virus that can lead to serious disease or death in people with compromised immune systems. The experimental drug has received an orphan drug designation from both European and U.S. regulators. That could lead to market exclusivity if the drug is approved.

The companies expect the deal to close by the end of this year, next year's first quarter or soon after that.

ViroPharma shares soared nearly 26 percent, or $10.19, to $49.57 Monday in premarket trading. The stock has more than doubled after closing 2012 at $22.76.

U.S.-traded shares of Shire climbed 3.7 percent, or $4.92, to $139.32.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Research Lends Hope for Patients With Rare Swelling Disease

Aug 10, 2010

(PhysOrg.com) -- The results of two recent clinical trials offer promising treatments for sufferers of the rare genetic disease hereditary angiodema, says Jonathan Bernstein, MD, an internationally recognized allergy specialist ...

FDA relents from midodrine withdrawal plan

Sep 06, 2010

(AP) -- Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

Huge yawn locks jaw, chokes man

Nov 19, 2007

A British man was rushed to the hospital after his monster yawn locked his jaw, blocking his ability to breathe or swallow.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

13 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments